Intermediate High Risk (IHR) PE: The value of a PE Lysis Team (PELT)

C. Carter (London, United Kingdom), T. Mason (London, United Kingdom), B. Lams (London, United Kingdom), B. Mukherjee (London, United Kingdom), N. Karunanithy (London, United Kingdom), B. Hunt (London, United Kingdom), K. Breen (London, United Kingdom), A. West (London, United Kingdom)

Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Session: Epidemiology, diagnosis and management of pulmonary embolism
Session type: E-poster session
Number: 3582

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Carter (London, United Kingdom), T. Mason (London, United Kingdom), B. Lams (London, United Kingdom), B. Mukherjee (London, United Kingdom), N. Karunanithy (London, United Kingdom), B. Hunt (London, United Kingdom), K. Breen (London, United Kingdom), A. West (London, United Kingdom). Intermediate High Risk (IHR) PE: The value of a PE Lysis Team (PELT). 3582

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pulmonary Embolism Lysis Team (PELT): Guiding thrombolysis in Sub-Massive PE (SMPE)
Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism
Year: 2017

Using Step Count to Enhance Daily Physical Activity in PH, a pilot-study (STEP in PH).
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019


Selection of patients from Pulmonary Rehabilitation (PR) to Disease Management (DM) programmes
Source: International Congress 2017 – Latest insights into the management of chronic lung diseases
Year: 2017

Effects of Pulmonary Rehabilitation (PR) on Exercise Capacity (EC) and Quality of Life (QOL) in Indian Patients with Severe COPD
Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD
Year: 2017

Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block.
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Patient and Public Involvement (PPI) in TANDEM: A Tailored intervention for ANxiety and DEpression Management in COPD
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017


A service evaluation of the accuracy of the Gold Standard Framework Proactive Indicator Guidance (GSF PIG)  in predicting 12 month mortality in patietns with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD).
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018




Prevalence and Risk Factors of Asthma and Allergy-Related Diseases among Adolescents (PERFORMANCE) study: rationale and methods
Source: ERJ Open Res, 4 (2) 00034-2018; 10.1183/23120541.00034-2018
Year: 2018



Imaging (Workshop)
Source:
Year: 2016

Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
Source: Virtual Congress 2021 – COVID-19 acute respiratory distress syndrome
Year: 2021



Clinical Impact of 2 types of Mandibular Retention Devices (MRD) - Narval CADCAM vs Narval nonCADCAM – on OSA: ESTAMPS STUDY
Source: International Congress 2018 – Treatments that can serve as an alternative to positive airway pressure (PAP)
Year: 2018

Feasibility and Validation Testing of the Walk.Talk.Track. (WTT) App for Remote Monitoring of the Six Minute Walk Test (6MWT) in Pulmonary Arterial Hypertension (PAH).
Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Year: 2021



Role of the PE rule-out criteria (PERC) in patients with suspected pulmonary embolism (PE) in a UK District General Hospital
Source: International Congress 2016 – Acute pulmonary embolism
Year: 2016


Late Breaking Abstract - Patient Reported Outcomes (PRO) Correlate Better with Intra-Breath than with Whole-Breath FOT Parameters.
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017

Sincope is a risk marker in Pulmonary Embolism (PE) with a low risk clinical profile (sPESI:0)
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019


Knowing asthma in adolescentes from Uruguaiana: The Global Asthma Network (GAN)
Source: International Congress 2019 – Aetiology and management of childhood respiratory infections, primary ciliary dyskinesia and asthma
Year: 2019


Asthma Control and the Influence of Valved Holding Chamber (VHC) Type: Results from a Real World, Retrospective Study
Source: International Congress 2017 – Bronchial asthma management
Year: 2017

Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB)
Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring
Year: 2010


Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network
Source: Eur Respir J, 51 (1) 1701937; 10.1183/13993003.01937-2017
Year: 2018



Development and first validation of the COugh Assessment Test (COAT)
Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence
Year: 2017